<DOC>
	<DOCNO>NCT02885038</DOCNO>
	<brief_summary>Platelet concentrate ( PCs ) characteristic , storage duration , ABO compatibility , dose source , may impact transfusion response outcomes . Because relative scarcity PCs selection specific PC issue patient remain challenging process . Regulatory agency fully address characteristic recommendation prophylactic transfusion . The aim study analyse effect product-related factor real life setting , order determine one relevant select PCs patient prophylactic condition . Two different endpoint study : correct count increment platelet transfusion time interval .</brief_summary>
	<brief_title>Effect Product Related Factors Platelet Concentrate Transfusion Response Patients With Hematologic Malignacies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inpatients hematology department January 2001 December 2012 Hematologic malignancy At least one platelet transfusion ( platelet count â‰¤ 25 G/L ) Age 18 time first transfusion More one hematologic malignancy Nonmalignant haematological disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Platelet Transfusion</keyword>
</DOC>